177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
Active, not recruiting · NCT04663997 · Registry updated 2026-03-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 2 | 2026-03-27 | NCT04663997 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Canadian Cancer Trials Group | 73 |
| Novartis Pharmaceuticals | 432 |
| Prostate Cancer Canada | 4 |
10 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| BCCA - Vancouver Cancer Centre | Vancouver | Canada | 11 |
| CHUM-Centre Hospitalier de l'Universite de Montreal | Montreal | Canada | 20 |
| CIUSSS de l'Estrie - Centre hospitalier | Sherbrooke | Canada | 7 |
| Cross Cancer Institute | Edmonton | Canada | 146 |
| Hotel-Dieu de Quebec | Québec | Canada | 10 |
| London Regional Cancer Program | London | Canada | 15 |
| Odette Cancer Centre | Toronto | Canada | 20 |
| The Jewish General Hospital | Montreal | Canada | 20 |
| Tom Baker Cancer Centre | Calgary | Canada | 29 |
| University Health Network | Toronto | Canada | 52 |